Raseen Tariq1,2, Janice Cho3, Saloni Kapoor1, Robert Orenstein4, Siddharth Singh5, Darrell S Pardi1, Sahil Khanna1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 2. Division of Internal Medicine, Rochester General Hospital, New York. 3. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 4. Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, Arizona. 5. Division of Gastroenterology and Hepatology, University of California San Diego, La Jolla.
Abstract
Background: The choice of antibiotics for systemic infections in patients with a high risk of Clostridium difficile infection (CDI) remains a clinical practice dilemma. Although some studies suggest that tetracyclines may be associated with a lower risk of CDI than other antibiotics, other results are conflicting. We conducted a systematic review and metaanalysis of studies that assessed the risk of CDI with tetracyclines compared to other antibiotics. Methods: We conducted a systematic search of Medline, Embase, and Web of Science from January 1978 through December 2016 to include studies that assessed the association between tetracycline use and risk of CDI. Weighted summary estimates were calculated using generalized inverse variance with a random-effects model using RevMan 5.3. Study quality was assessed using the Newcastle-Ottawa scale. Results: Six studies (4 case control, 2 cohort) with patient recruitment between 1993 and 2012 were included. Metaanalysis using a random-effects model, demonstrated that tetracyclines were associated with a decreased risk of CDI (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.47-0.81; P < .001). There was significant heterogeneity, with an I2 of 53% with no publication bias. Subgroup analysis of studies that evaluated the risk of CDI with doxycycline alone also demonstrated a decreased risk of CDI (OR, 0.55; 95% CI, 0.40-0.75; P < .001). Conclusions: Metaanalyses of existing studies suggest that tetracyclines may be associated with a decreased risk of CDI compared with other antimicrobials. It may be reasonable to use tetracyclines whenever appropriate to decrease CDI associated with antibiotic use.
Background: The choice of antibiotics for systemic infections in patients with a high risk of Clostridium difficile infection (CDI) remains a clinical practice dilemma. Although some studies suggest that tetracyclines may be associated with a lower risk of CDI than other antibiotics, other results are conflicting. We conducted a systematic review and metaanalysis of studies that assessed the risk of CDI with tetracyclines compared to other antibiotics. Methods: We conducted a systematic search of Medline, Embase, and Web of Science from January 1978 through December 2016 to include studies that assessed the association between tetracycline use and risk of CDI. Weighted summary estimates were calculated using generalized inverse variance with a random-effects model using RevMan 5.3. Study quality was assessed using the Newcastle-Ottawa scale. Results: Six studies (4 case control, 2 cohort) with patient recruitment between 1993 and 2012 were included. Metaanalysis using a random-effects model, demonstrated that tetracyclines were associated with a decreased risk of CDI (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.47-0.81; P < .001). There was significant heterogeneity, with an I2 of 53% with no publication bias. Subgroup analysis of studies that evaluated the risk of CDI with doxycycline alone also demonstrated a decreased risk of CDI (OR, 0.55; 95% CI, 0.40-0.75; P < .001). Conclusions: Metaanalyses of existing studies suggest that tetracyclines may be associated with a decreased risk of CDI compared with other antimicrobials. It may be reasonable to use tetracyclines whenever appropriate to decrease CDI associated with antibiotic use.
Authors: Sarah E Schall; Ping Li; Timothy J Whitman; Joseph L Petfield; David R Tribble; Dana M Blyth Journal: Infect Control Hosp Epidemiol Date: 2020-06-30 Impact factor: 3.254
Authors: Kevin Antoine Brown; Bradley Langford; Kevin L Schwartz; Christina Diong; Gary Garber; Nick Daneman Journal: Clin Infect Dis Date: 2021-03-01 Impact factor: 9.079
Authors: Ioannis M Zacharioudakis; Fainareti N Zervou; Fadi Shehadeh; Evangelia K Mylona; Eleftherios Mylonakis Journal: EClinicalMedicine Date: 2019-02-19